Neutron Therapeutics, Inc.

Name

Neutron Therapeutics, Inc.

Legal name

Neutron Therapeutics, LLC.

Website

https://neutrontherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Radiation Therapy Equipment

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Reactor Core Design, Neutronics & Thermal-Hydraulics Engineering Tools (EUAKADAD)

Keywords

• Boron Neutron Capture Therapy
• Neutron Beam Therapy
• Radiation Therapy Equipment
• Proton Accelerator Systems
• Cancer Treatment Systems

Headquarters

HQ city

Danvers

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Medical Equipment Sales: Sale of nuBeam BNCT suites (accelerator-based neutron source, treatment room equipment, shielding solutions) to hospitals and cancer treatment centers. The system is sold as a complete therapeutic treatment suite combining all necessary components for BNCT treatment.
2. Professional Services: Installation, commissioning, clinical training, and ongoing technical support services for the nuBeam system. Collaboration with hospital partners on clinical studies and drug development for BNCT.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Neutron Therapeutics develops and manufactures the nuBeam BNCT Suite, a compact accelerator-based neutron source for Boron Neutron Capture Therapy (BNCT) that enables in-hospital cancer treatment. The system combines a 2.6 MeV electrostatic proton accelerator with a rotating solid lithium target, beam-shaping assembly, patient positioning systems, and ancillary equipment, replacing the nuclear reactors previously required for BNCT. The company sells this complete single-room BNCT solution directly to hospitals and cancer treatment centers along with installation, commissioning, clinical training, and ongoing support services.

Product overview

Neutron Therapeutics offers a single-room BNCT solution centered on the nuBeam Suite—an accelerator-based, in-hospital neutron source that replaces the nuclear reactors previously required for BNCT. The nuBeam Suite combines a 2.6 MeV electrostatic proton accelerator with a rotating solid lithium target, beam-shaping assembly, patient positioning systems, treatment control software, and integration with RayStation treatment planning software. The company also provides custom shielding bunker solutions. All products are investigational and not yet approved by FDA, EMA, or PMDA.

Differentiator

Problem solved

Functional benefit

Brands

• nuBeam: A compact accelerator-based neutron source system for in-hospital BNCT treatment, including beam-shaping assembly, patient positioning systems, ancillary equipment, and shielding bunker solutions.

Products and services

• nuBeam Suite A complete single-room Boron Neutron Capture Therapy (BNCT) solution including a 2.6 MeV electrostatic proton accelerator, rotating solid lithium target, beam-shaping assembly, patient positioning systems, treatment control software, and ancillary equipment, plus custom-designed shielding bunker solutions. Designed for in-hospital installation as a compact alternative to nuclear reactors for cancer treatment.

Quantifiable outcome

• Neutron flux of 1.34 x 10^9 neutrons/cm2/s, exceeding IAEA minimum recommendation of 1.0 x 10^9 neutrons/cm2/s for BNCT
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• University of BirminghamcoreStrategic or Co-development Partner · 13 December 2022UK's first high-flux neutron test facility as part of National Nuclear User Facility (NNUF) program, funded by EPSRC. Neutron Therapeutics' compact accelerator received final acceptance for use in the facility. Enables research in nuclear energy, nuclear science, and pre-clinical BNCT research. Capabilities include 30 mA nominal proton current, 2.6 MeV proton energy, and 3x10^13 primary neutrons per second yield.
• Tokushukai Medical GroupcoreStrategic or Co-development Partner · 16 July 2019Agreement to install nuBeam system at Shonan Kamakura General Hospital in Kanagawa Prefecture, Japan. TMG operates over 350 medical facilities including 71 hospitals, making it Japan's largest private hospital group. nuBeam to be housed in new Comprehensive Cancer Center under construction at SKGH.
• RaySearchcoreTechnology or Integration · 6 November 2017Agreement for treatment planning for BNCT. RayStation's functionality extended to support BNCT planning requirements. Neutron Therapeutics' complete single-room solution includes dose engine interfaced to RayStation treatment planning system. BNCT added as additional treatment modality alongside photon, electron, proton, and carbon ion therapy.
• Helsinki University HospitalcoreStrategic or Co-development Partner · 15 September 2016HUH Cancer Center acquired nuBeam suite for BNCT. Collaboration on developing BNCT towards clinical use in multiple cancer indications. HUH has successfully applied BNCT to over 200 cancer patients using research reactor. The partnership led to Europe's first in-hospital accelerator-based BNCT facility with first patients treated in May 2025.
• Buckley SystemscoreTechnology or Integration · 15 September 2016NZ precision electro magnets manufacturer involved in development and manufacture of nuBeam proton accelerator. Bill Buckley, President of Buckley Systems, acquired accelerator assets and IP from GT Advanced Technologies. Buckley Systems upgraded precision electro magnets to deliver required neutron output (2.6 MeV vs original 2 MeV). Described as three-way partnership with Danvers team and Finnish medical experts.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• ProNova Solutions: ProNova develops compact superconducting proton therapy systems targeting community hospitals. Comparable as an emerging compact particle therapy player pursuing similar in-hospital, smaller-footprint positioning in cancer treatment capital equipment.
• Mevion Medical Systems: Mevion develops compact single-room proton therapy systems (MEVION S250-FIT), targeting the same in-hospital, lower-cost-of-ownership positioning that Neutron Therapeutics uses for nuBeam. Comparable as a smaller, technology-focused particle therapy challenger.

Broad incumbents

• Varian Medical Systems (Siemens Healthineers): Varian is the largest radiation oncology equipment manufacturer globally, offering linear accelerators, treatment planning, and proton therapy solutions. As a broad incumbent in hospital-based radiation therapy, it represents the dominant incumbent Neutron Therapeutics must displace or partner with for BNCT adoption.
• Hitachi: Hitachi has developed BNCT systems and broader particle therapy solutions including proton therapy equipment for hospitals. It represents a large incumbent with overlapping radiation therapy capabilities and significant hospital relationships in Japan.
• IBA (Ion Beam Applications): IBA is the world's leading provider of proton therapy systems with ProteusONE and ProteusPLUS installations globally. As an accelerator-based particle therapy incumbent, it represents the established alternative for hospitals considering next-generation radiation therapy capital equipment.
• Elekta: Elekta is a global leader in radiation therapy and radiosurgery equipment (Leksell Gamma Knife, linear accelerators), serving comprehensive cancer centers worldwide. It competes broadly in the same hospital oncology capital equipment purchasing budgets as Neutron Therapeutics.

Others

• RaySearch Laboratories: RaySearch is the treatment planning software partner for Neutron Therapeutics (RayStation integration for BNCT). As the leading independent radiation oncology treatment planning vendor, it is an ecosystem enabler and integration partner rather than a direct competitor.
• Stella Pharma: Stella Pharma develops and supplies boron-10 delivery drugs (Steboronine/SPM-011) used in BNCT treatment. As the leading boron drug supplier in Japan, Stella Pharma is a critical ecosystem partner and dependency for any BNCT equipment provider including Neutron Therapeutics.

Direct peers

• Sumitomo Heavy Industries: Sumitomo Heavy Industries developed the NeuCure BNCT system, a cyclotron-based neutron source deployed at several Japanese hospitals. As the most established commercial BNCT system operator, it is the most direct comparable to Neutron Therapeutics' nuBeam platform.
• TAE Life Sciences: TAE Life Sciences (subsidiary of TAE Technologies) develops the Alphabeam accelerator-based BNCT system targeting in-hospital cancer treatment. As a direct competitor in accelerator-based BNCT, it competes head-to-head with Neutron Therapeutics' nuBeam platform in Western markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neutron Therapeutics, Inc.